Current Treatment Strategies for Rheumatoid Arthritis
Identifieur interne : 002470 ( Main/Exploration ); précédent : 002469; suivant : 002471Current Treatment Strategies for Rheumatoid Arthritis
Auteurs : Eric L. MattesonSource :
- Mayo Clinic Proceedings [ 0025-6196 ] ; 2000.
English descriptors
- Teeft :
- Acceptable alternative, Active disease, Adverse effects, Antirheumatic, Antirheumatic drugs, Arthritis, Arthritis rheum, Clin, Clinical course, Combination therapy, Current treatment, Cyclosporine, Disease control, Disease manifestations, Dmard, Dmard antirheumatic drug, Dmard therapy, Dmards, Dos, Empty stomach, Etanercept, Glucocorticoid, Good disease outcome, Gradual onset, High risk, Hydroxychloroquine, Individual patient, Infliximab, Injection site, Leflunomide, Liquid form, Many rheumatologists, Mayo, Mayo clin proc, Mayo clinic proceedings, Mayo clinic rochester, Methotrexate, Mild disease, Morning stiffness, Myeloproliferative disorders, Myelosuppression, Nonsteroidal drugs, Nsaid, Nsaid nonsteroidal drug, Oral prednisone, Platelet, Platelet count, Polyarticular arthritis, Prednisone, Previous history, Primary care physician, Proc, Renal insufficiency, Rheumatoid, Rheumatoid arthritis, Rheumatoid factor, Rheumatoid vasculitis, Rheumatologist, Severe disease, Single dose, Sulfasalazine, Systemic vasculitis, Toxic effects, Toxicity profile, Tumor necrosis factor, Urine dipstick, Vasculitis, Weight loss.
Abstract
The management of rheumatoid arthritis has changed considerably during the past 15 years. Current strategies emphasize the need for early diagnosis and therapeutic intervention based on the use of disease-modifying antirheumatic drugs. The advent of agents that are more tailored to inhibit the specific disease processes will profoundly affect management. Immunogenetic studies may eventually assist in identifying subgroups of patients with rheumatoid arthritis who have more aggres sive disease and who require a more aggressive treatment approach.
Url:
DOI: 10.4065/75.1.69
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000342
- to stream Istex, to step Curation: 000342
- to stream Istex, to step Checkpoint: 001287
- to stream Main, to step Merge: 002498
- to stream Main, to step Curation: 002470
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Current Treatment Strategies for Rheumatoid Arthritis</title><author><name sortKey="Matteson, Eric L" sort="Matteson, Eric L" uniqKey="Matteson E" first="Eric L." last="Matteson">Eric L. Matteson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4D76E497B6C0BEF09AFC29D6553A19378FBB93B9</idno><date when="2000" year="2000">2000</date><idno type="doi">10.4065/75.1.69</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-X5PZ94C4-S/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000342</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000342</idno><idno type="wicri:Area/Istex/Curation">000342</idno><idno type="wicri:Area/Istex/Checkpoint">001287</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001287</idno><idno type="wicri:doubleKey">0025-6196:2000:Matteson E:current:treatment:strategies</idno><idno type="wicri:Area/Main/Merge">002498</idno><idno type="wicri:Area/Main/Curation">002470</idno><idno type="wicri:Area/Main/Exploration">002470</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Current Treatment Strategies for Rheumatoid Arthritis</title><author><name sortKey="Matteson, Eric L" sort="Matteson, Eric L" uniqKey="Matteson E" first="Eric L." last="Matteson">Eric L. Matteson</name><affiliation><wicri:noCountry code="subField">Minn.</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Mayo Clinic Proceedings</title><title level="j" type="abbrev">JMCP</title><idno type="ISSN">0025-6196</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">75</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="69">69</biblScope><biblScope unit="page" to="74">74</biblScope></imprint><idno type="ISSN">0025-6196</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0025-6196</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acceptable alternative</term><term>Active disease</term><term>Adverse effects</term><term>Antirheumatic</term><term>Antirheumatic drugs</term><term>Arthritis</term><term>Arthritis rheum</term><term>Clin</term><term>Clinical course</term><term>Combination therapy</term><term>Current treatment</term><term>Cyclosporine</term><term>Disease control</term><term>Disease manifestations</term><term>Dmard</term><term>Dmard antirheumatic drug</term><term>Dmard therapy</term><term>Dmards</term><term>Dos</term><term>Empty stomach</term><term>Etanercept</term><term>Glucocorticoid</term><term>Good disease outcome</term><term>Gradual onset</term><term>High risk</term><term>Hydroxychloroquine</term><term>Individual patient</term><term>Infliximab</term><term>Injection site</term><term>Leflunomide</term><term>Liquid form</term><term>Many rheumatologists</term><term>Mayo</term><term>Mayo clin proc</term><term>Mayo clinic proceedings</term><term>Mayo clinic rochester</term><term>Methotrexate</term><term>Mild disease</term><term>Morning stiffness</term><term>Myeloproliferative disorders</term><term>Myelosuppression</term><term>Nonsteroidal drugs</term><term>Nsaid</term><term>Nsaid nonsteroidal drug</term><term>Oral prednisone</term><term>Platelet</term><term>Platelet count</term><term>Polyarticular arthritis</term><term>Prednisone</term><term>Previous history</term><term>Primary care physician</term><term>Proc</term><term>Renal insufficiency</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid factor</term><term>Rheumatoid vasculitis</term><term>Rheumatologist</term><term>Severe disease</term><term>Single dose</term><term>Sulfasalazine</term><term>Systemic vasculitis</term><term>Toxic effects</term><term>Toxicity profile</term><term>Tumor necrosis factor</term><term>Urine dipstick</term><term>Vasculitis</term><term>Weight loss</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">The management of rheumatoid arthritis has changed considerably during the past 15 years. Current strategies emphasize the need for early diagnosis and therapeutic intervention based on the use of disease-modifying antirheumatic drugs. The advent of agents that are more tailored to inhibit the specific disease processes will profoundly affect management. Immunogenetic studies may eventually assist in identifying subgroups of patients with rheumatoid arthritis who have more aggres sive disease and who require a more aggressive treatment approach.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Matteson, Eric L" sort="Matteson, Eric L" uniqKey="Matteson E" first="Eric L." last="Matteson">Eric L. Matteson</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002470 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002470 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4D76E497B6C0BEF09AFC29D6553A19378FBB93B9
|texte= Current Treatment Strategies for Rheumatoid Arthritis
}}
| This area was generated with Dilib version V0.6.33. |  |